Federal Gov't Said to Claim Mylan (MYL) Overcharged Medicaid Over EpiPen
Find out which companies are about to raise their dividend well before the news hits the Street with StreetInsider.com's Dividend Insider Elite. Sign-up for a FREE trial here.
Mylan (Nasdaq: MYL) shares are on watch following news that the Federal government is accusing the company of overcharging the Medicaid program by millions of dollars for its EpiPen product.
The WSJ noted commentary from Acting Administrator Andy Slavitt of the federal Centers for Medicare and Medicaid Services (CMS) in a letter on Wednesday.
Slavitt said Mylan incorrectly classified EpiPen as generic, when it should have been classified as brand name. That allow Mylan to pay a rebate of just 13%, or around $163 million, versus a rebate of 23.1 percent or more than it should've been paying.
Slavitt noted that the CMS has,
on multiple occasions provided guidance to the industry and Mylan on the proper classification of drugs and has expressly told Mylan that the product is incorrectly classified.
Shares of Mylan are flat Thursday morning.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UPDATE: Cvent, Inc. (CVT) Active on Reports of DOJ Probe into Deal
- Volatility and Volume movement
- Mallinckrodt (MNK) Announces Court Affirmation to Stay Litigation Pending FDA’s Approval Withdrawal Proceedings Outcome
Create E-mail Alert Related CategoriesLitigation, Trader Talk
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!